From: CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy
Response to treatment
n = 78, n (%)
Response at first assessment:
• Complete response
9 (11)
• Partial response
16 (21)
• Stable disease
17 (22)
• Progression disease
36 (46)
ORR
25 (32)
DCR
39 (50)